Compare Marathon Digital Holdings Inc (MARA) vs Novavax Inc (NVAX) Price & Performance

MARA stock trades at $9.71, down 6.27% on the day, reflecting a volatile trend. The technical outlook is bearish overall, with moving averages signaling a downtrend, though oscillators suggest potential for a short-term bounce. Fundamentally, the company reported a net loss of $1.31 billion in 2025 with a negative net income margin of -429.71%, despite a high gross margin of 76.71%. Recent earnings have consistently missed expectations, with Q2 2026 EPS of -1.6 missing the expected 0.1666. Analyst sentiment is mixed, with a consensus price target of $13.25.

The outlook for MARA is challenged by persistent losses and negative profitability metrics, though low valuation ratios like a P/E of 3.37 may attract value investors. Key risks include execution challenges in achieving profitability, high cash burn from operations, and sensitivity to broader market sentiment. The stock's performance remains heavily influenced by news flow and sector momentum, requiring careful risk assessment for potential investors.

Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.

Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.